Compatibility of pentoxifylline and parenteral medications
MetadataShow full item record
Objective: To investigate the physical and chemical compatibility of pentoxifylline (PTX) with a range of parenteral medications used in neonatal intensive care.
Design: PTX and drug solutions were combined in glass vials, inspected for physical incompatibility and evaluated on the basis of PTX concentrations for chemical compatibility.
Results: No precipitation, colour change or turbidity was observed in any of the test mixtures. The PTX concentration was approximately 5.5% lower when combined with undiluted calcium gluconate injection (100 mg/mL). The PTX concentration ratios for all other combinations, including diluted calcium gluconate injection (50 mg/mL), were in the range of 99.5%-102%.
Conclusion: In simulated Y-site conditions, PTX was found to be compatible with 15 parenteral medications and six total parenteral nutrition solutions. Based on PTX concentration tests, it would be prudent to avoid mixing PTX with undiluted calcium gluconate injection.
Showing items related by title, author, creator and subject.
Senarathna, S.; Strunk, T.; Petrovski, M.; Batty, Kevin (2018)OBJECTIVE: To investigate the physical and chemical compatibility of pentoxifylline (PTX) with a wide range of parenteral medications used in the neonatal intensive care setting. DESIGN: PTX and drug solutions were combined ...
Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysisHolman, R.; Olynyk, John; Kulkarni, H.; Ferrari, P. (2017)Background: Parenteral iron is integral in the treatment of anaemia of chronic kidney disease patients on haemodialysis (HD). However, increased liver iron concentration (LIC) can result from such treatment, and this ...
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysisMaker, G.; Siva, B.; Batty, Kevin; Trengove, R.; Ferrari, P.; Olynyk, John (2013)AIM: Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is ...